Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login

Inducible Cre Mouse Enhances Pancreatic Gene Knockouts

Cyagen Technical Content Team | July 13, 2025
Pdx1-CreERT2 Mouse
Target islet cell gene expression with the Pdx1-CreERT2 strain. Ideal for pancreatic development and β-cell studies in academic and biotech research.
Pdx1-CreERT2 Mouse
Contents
01. PDX1 Gene: A Key to Pancreatic Organogenesis and β-cell Function 02. Pdx1-CreERT2 Mice Exhibit Higher Pancreas-Specific Recombination Efficiency than Pdx1-Cre Mice 03. Cre Recombinase Exhibits Limited Expression in the Duodenum and Thymus 04. The Pdx1-CreERT2 Mouse Model Exhibits Good Tissue Specificity 05. Summary 06. References

The Cre-Lox system allows for gene knockout/knockin in specific cells/tissues, with the timing of its expression is determined by the promoter. To further achieve dual control of gene expression in terms of both time and space, ligand-dependent CreER recombinase was developed. CreER is composed of Cre recombinase fused with the hormone-binding domain of the estrogen receptor. In the absence of the estrogen analog tamoxifen, the recombinase is mainly present in the cytoplasm. Only under the action of tamoxifen can the recombinase enter the cell nucleus and exert its recombination function. CreERT2 is an upgraded version of the CreER recombinase with three point mutations (G400V/M543A/L544A) in the estrogen-binding domain, which reduces background activity when uninduced while increasing tamoxifen sensitivity and induction efficiency. Today, we introduce the improved pancreas-specific cre driver mouse line — the Pdx1-CreERT2 mouse model (Product No.: C001537).

PDX1 Gene: A Key to Pancreatic Organogenesis and β-cell Function

The PDX1 gene encodes a protein that is a major regulator of pancreatic organogenesis, β-cell maturation and maintenance, and normal insulin function. Activation of the PDX1 gene promotes insulin release and the expression of important genes in β-cells, making it necessary for pancreatic stem cells to differentiate into pancreatic β-cells. Thus, PDX1 is an important target for gene or replacement therapies for diabetes.[1]

Research has found that PDX1 protein maintains the characteristics and functions of β-cells by inhibiting the differentiation of α-cells, and pancreatic β-cells can survive and undergo β-to-α cell reprogramming in the absence of PDX1.[2] PDX1 is specifically expressed in early pancreatic epithelium and plays a role in proliferation and differentiation during development. At the adult stage, PDX1 is essential for hormne production in β-cells. PDX1 is one of the earliest expressed transcription factors during pancreatic development and continues to be expressed during β-cell maturation.[1,3] Besides its expression in β-cells and some δ-cells, it is also expressed in the gastrointestinal tract (such as the duodenum) and the central nervous system during development.[4-5]

The role of PDX1 in pancreatic organogenesis and β-cell maturation.[1]
Figure 1. The role of PDX1 in pancreatic organogenesis and β-cell maturation.[1]

Pdx1-CreERT2 Mouse Model for Targeted Pancreatic Research

Cyagen has independently developed the Pdx1-CreERT2 mouse (Product No.: C001537) using gene editing technology to provide a liver-specific Cre driver mouse line with exceptional temporal control for gene research and preclinical studies. The Pdx1-CreERT2 mouse model expresses the CreERT2 recombinase under the control of the mouse Pdx1 gene regulatory elements. Once Pdx1-CreERT2 mice are crossed with mice containing loxP sites, tamoxifen induction can trigger Cre recombinase-mediated recombination between the loxP sites in the pancreas of the offspring.

Tamoxifen Induction of Pancreas Tissue-Specific Gene Recombination

Without tamoxifen treatment, CreERT2 recombinase primarily resides in the cytoplasm. Only when tamoxifen is administered does the CreERT2 recombinase enter the cell nucleus and exert its recombination activity. When Pdx1-CreERT2 mice are crossed with mice containing loxP sites, tamoxifen induction can trigger sequence recombination between loxP sites mediated by Cre recombinase in the pancreatic cells of the offspring. It’s important to note that without tamoxifen treatment, there may be some leakage of CreERT2 recombinase expression before induction. The insertion site of the Cre recombinase gene expression cassette in this strain is located on chromosome 5, so breeding with gene-edited mice targeting genes on the same chromosome as the Cre mouse should be avoided when conducting mating.

Pdx1-CreERT2 Mice Exhibit Higher Pancreas-Specific Recombination Efficiency than Pdx1-Cre Mice

Expression of Cre recombinase in the pancreas shown by fluorescence microscopy.
Figure 2. Expression of Cre recombinase in the pancreas shown by fluorescence microscopy.

After Pdx1-CreERT2 mice are crossed with ROSA26-LSL-tdTomato mice, which conditionally express tdTomato fluorescent protein, the expression of CreERT2 recombinase is induced in the double transgenic offspring by treatment with tamoxifen or corn oil. The fluorescence microscopy results show a significant amount of tdTomato fluorescence signal in the pancreas of the tamoxifen-treated group, indicating high recombinase activity. Additionally, compared to non-inducible Pdx1-Cre mice, the Pdx1-CreERT2 mice exhibit significantly higher recombination efficiency in the pancreas.

Cre Recombinase Exhibits Limited Expression in the Duodenum and Thymus

Fluorescence microscopy demonstrating the expression of Cre recombinase in the duodenum and thymus.
Figure 3. Fluorescence microscopy demonstrating the expression of Cre recombinase in the duodenum and thymus.
Following the previous method of crossing Pdx1-CreERT2 mice with ROSA26-LSL-tdTomato mice, the expression of CreERT2 recombinase is induced in the offspring by treatment with tamoxifen or corn oil. The fluorescence microscopy results show partial red fluorescence signals in the duodenal villi and thymus of the tamoxifen-treated group, demonstrating additional tissues that may be affected by the induction of gene modification.

The Pdx1-CreERT2 Mouse Model Exhibits Good Tissue Specificity

Immunofluorescence (IF) shows no demonstrable expression of Cre recombinase in other tissues tested, including the stomach, uterus, ovaries, lungs, liver, and brain.

Figure 4. Immunofluorescence (IF) shows no demonstrable expression of Cre recombinase in other tissues tested, including the stomach, uterus, ovaries, lungs, liver, and brain.
When Pdx1-CreERT2 mice are crossed with ROSA26-LSL-tdTomato mice and their offspring are treated with tamoxifen or corn oil, no significant recombination signals are detected in the stomach, uterus, ovaries, lungs, liver, and brain tissues of either the tamoxifen-treated group or the corn oil-treated group. This indicates that the Pdx1-CreERT2 mouse exhibits good tissue specificity, with high targeting of the pancreas and detargeting of other major tissues.

Summary

The Pdx1-CreERT2 mouse model (Product No.: C001537) has demonstrated high expression of Cre recombinase in the pancreas, with minimal fluorescence signals observed in the duodenum and thymus indicating trace recombination events. No recombination signals are detected under fluorescence microscopy in the stomach, uterus, ovaries, lungs, liver, and brain — indicating detargeting of other major tissues. Therefore, the Pdx1-CreERT2 mouse model demonstrates good specificity for use in targeted genetic research on pancreatic islet cell tissues.

References

[1] Ebrahim N, Shakirova K, Dashinimaev E. PDX1 is the cornerstone of pancreatic β-cell functions and identity. Front Mol Biosci. 2022 Dec 15;9:1091757.

[2] Gao T, McKenna B, Li C, Reichert M, Nguyen J, Singh T, Yang C, Pannikar A, Doliba N, Zhang T, Stoffers DA, Edlund H, Matschinsky F, Stein R, Stanger BZ. Pdx1 maintains β cell identity and function by repressing an α cell program. Cell Metab. 2014 Feb 4;19(2):259-71.

[3] Jennings RE, Berry AA, Kirkwood-Wilson R, Roberts NA, Hearn T, Salisbury RJ, Blaylock J, Piper Hanley K, Hanley NA. Development of the human pancreas from foregut to endocrine commitment. Diabetes. 2013 Oct;62(10):3514-22.

[4] Ma J, Chen M, Wang J, Xia HH, Zhu S, Liang Y, Gu Q, Qiao L, Dai Y, Zou B, Li Z, Zhang Y, Lan H, Wong BC. Pancreatic duodenal homeobox-1 (PDX1) functions as a tumor suppressor in gastric cancer. Carcinogenesis. 2008 Jul;29(7):1327-33.

[5] Perez-Villamil B, Schwartz PT, Vallejo M. The pancreatic homeodomain transcription factor IDX1/IPF1 is expressed in neural cells during brain development. Endocrinology. 1999 Aug;140(8):3857-60.

Frequently Asked Questions (FAQs)

What is the Cre-Lox system and how does it achieve tissue-specific knockout?

The Cre-Lox system consists of Cre recombinase and LoxP sites. By crossing a Cre mouse model line (driven by a tissue-specific promoter) with a Floxed mouse, the gene of interest is only excised in tissues where Cre is expressed. This allows for localized gene deletion and bypasses the potential embryonic lethality associated with global knockouts.

How to Genotype Cre Flox Mice​?

Genotyping Cre-Flox mice is a critical step in preclinical research to confirm the presence of both the Cre recombinase transgene and the floxed alleles (LoxP-flanked DNA segments) in your experimental cohort. This process ensures that gene deletion occurs only in the targeted tissues at the intended time.
Subscribe to Receive Updates & Promotions From Cyagen
Subscribe
* Your privacy matters to us. We never share it with third parties.
Explore More
In Vivo CAR-T Enters Clinical Validation: How It Works and What Comes Next
Beyond Subretinal Injections: How AI is Reshaping AAV Capsid Engineering for Retinal Gene Therapy
Why Eli Lilly is Targeting Nav1.8 and MNK for Next-Gen Pain Therapeutics
Mastering AAV Cardiac Delivery: Serotypes, Promoters, and Ready-to-Use Models
Share
Top
Ready to Elevate Your Research?
Discover how Cyagen can support your research. Let’s start a conversation.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research